Purdue Is Open For Business Deals And Shopping On Multiple Fronts
The private pain specialist is interested in business development opportunities in its core therapeutic space and adjacencies, but also looking at other ‘innovative’ technologies and partnerships with ex-US drug manufacturers, CEO Timney said during an interview.
You may also be interested in...
Keeping Track Of Non-Oncology Review and Approval News: Erectile Dysfunction, Parkinson's, Cholesterol
The latest non-oncology drug development news and highlights from our US FDA Performance Tracker.
In its continuing efforts to diversify away from opioid pain drugs, Purdue partners on non-opioid program with Alivio. Rigel licenses Tavalisse rights in all indications go to Spain’s Grifols.
A new report released during the BIO CEO conference shows novel pain therapy candidates face a high failure rate, which may help explain why smaller, privately held biotechs aren't very active in the space.